Max Robotics — Global Service Robot Directory + US Certification

About

Michael Chaloupka is a leading urological surgeon and researcher whose work centers on advancing surgical outcomes for prostate and testicular cancers through large-scale, real-world data analysis. His major contributions include pioneering the use of the GeRmAn Nationwide inpatient Data (GRAND) study register to evaluate the evolution and perioperative safety of robotic urology, demonstrating that robot-assisted radical prostatectomy (RARP) offers measurable benefits in health-related quality of life compared to open surgery for low- and intermediate-risk prostate cancer patients. His research on focal therapy complications and retroperitoneal lymph node dissection for testicular cancer provides critical evidence guiding surgical decision-making. With his most-cited paper accumulating 29 citations and several studies published in 2024-2025, Chaloupka’s work is gaining rapid recognition for filling gaps left by major urological guidelines. Notably, his propensity score-matched analysis on HRQOL after RARP versus open surgery (21 citations) has influenced clinical practice by highlighting patient-centered outcomes. Through the GRAND initiative, Chaloupka is shaping a new era of evidence-based, data-driven urology, making him a key voice in the ongoing debate over surgical standards in oncology.